| human | Q5 |
| P244 | Library of Congress authority ID | n2017180972 |
| P8189 | National Library of Israel J9U ID | 987007383903305171 |
| P496 | ORCID iD | 0000-0002-8494-6252 |
| P1153 | Scopus author ID | 6701688398 |
| P214 | VIAF ID | 9973148753717041320004 |
| P10832 | WorldCat Entities ID | E39PBJcBXrdVCXy9ybFfQ7YXVC |
| P69 | educated at | University of Milan | Q46210 |
| P108 | employer | University of Milan | Q46210 |
| P734 | family name | Cozzolino | Q37535068 |
| Cozzolino | Q37535068 | ||
| Cozzolino | Q37535068 | ||
| P735 | given name | Mario | Q3362622 |
| Mario | Q3362622 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q44104172 | 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor |
| Q44473265 | A biophysical integrated approach to autoimmune nephrotic syndrome: case report |
| Q87382093 | A comparison between two different definitions of contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention |
| Q53667768 | A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. |
| Q40566171 | A new in vitro model to delay high phosphate-induced vascular calcification progression. |
| Q86499433 | A renewed question in haemodialysis patients: should we correct low serum magnesium levels? |
| Q89637348 | Achieve Your Goals Together. The Easy and Reasonable Way to Treat Chronic Kidney Disease-Mineral Bone Disorder |
| Q44715948 | Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort |
| Q36906034 | Activator protein 2alpha mediates parathyroid TGF-alpha self-induction in secondary hyperparathyroidism |
| Q49994210 | Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders |
| Q90457617 | An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations |
| Q84228661 | Arterial accelerated aging in dialysis patients: the clinical impact of vascular calcification |
| Q83511658 | Awareness of hypertension and proteinuria in randomly selected patients in 11 Italian cities. A 2005 report of the National Kidney Foundation of Italy |
| Q38211205 | Balancing nutrition and serum phosphorus in maintenance dialysis |
| Q91538087 | Biophysical integrated approach for the management of early stages of CKD in elderly patients: a 12-month controlled study |
| Q38105763 | Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis |
| Q26785885 | Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet) |
| Q47738927 | Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. |
| Q40275241 | Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative-a position paper |
| Q47248898 | Bone in CKD: why the ERA EDTA CKD-MBD working group organized a dedicated meeting? |
| Q34418714 | Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. |
| Q82433082 | CCN2 (CTGF) gene polymorphism is a novel prognostic risk factor for cardiovascular outcomes in hemodialysis patients |
| Q84576509 | CKD patients: the dilemma of serum PTH levels |
| Q50022061 | CKD-MBD KDIGO guidelines: how difficult is reaching the 'target'? |
| Q37881940 | CKD-MBD: an endless story |
| Q38605841 | Calcifediol to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease. |
| Q38286696 | Calcific uremic arteriolopathy: a call for action. |
| Q39016562 | Calcifying circulating cells: an uncharted area in the setting of vascular calcification in CKD patients |
| Q92435140 | Calciphylaxis in a dialysis patient treated by intralesional and systemic sodium thiosulphate on top of multifactorial intervention |
| Q90688001 | Calciphylaxis-as a drug induced adverse event |
| Q34165867 | Calciphylaxis: a still unmet challenge |
| Q37417305 | Calcium and phosphate control by dialysis treatments. |
| Q36487275 | Calcium and phosphate handling in peritoneal dialysis. |
| Q81556332 | Calcium and phosphate: serum levels versus body balance |
| Q37959595 | Calcium-sensing receptor and calcium kidney stones |
| Q44855417 | Cardiac valve calcification: an immutable pathologic finding in chronic kidney disease? |
| Q30241023 | Cardiorenal acute kidney injury: Epidemiology, presentation, causes, pathophysiology and treatment. |
| Q57060378 | Cardiovascular disease in dialysis patients |
| Q57784986 | Chronic Hyperkalemia in Cardiorenal Patients: Risk Factors, Diagnosis, and New Treatment Options |
| Q87969148 | Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study |
| Q38410120 | Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial |
| Q80595536 | Cinacalcet, paricalcitol, or both? |
| Q39719456 | Cinacalcet: the chemical parathyroidectomy? |
| Q61659895 | Clinical Management of Chronic Kidney Disease Patients in Italy: Results from the IRIDE Study |
| Q50955565 | Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol). |
| Q36432849 | Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. |
| Q57221611 | Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients |
| Q48032432 | Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis. |
| Q84882493 | Clinical significance of FGF-23 measurement in dialysis patients |
| Q42733524 | Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation |
| Q42615996 | Conversion from epoetin and darbepoetin to C.E.R.A. in non-dialysis CKD patients: a multicenter Italian prospective study in nephrology practice. |
| Q28392247 | Correction of metabolic acidosis improves insulin resistance in chronic kidney disease |
| Q96116284 | Current Therapy in CKD Patients Can Affect Vitamin K Status |
| Q80142949 | Decreased serum fetuin-A levels after a single haemodialysis session |
| Q90958841 | Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial |
| Q89486495 | Differential diagnosis of calciphylaxis in chronic dialysis patients |
| Q44137817 | Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats |
| Q97645082 | ERA-EDTA sharing Milan experience on coronavirus management in dialysis centres |
| Q89780477 | Ectopic Calcification in Uremia: Where Do We Stand? |
| Q51724973 | Editorial: vitamin D therapy: an update available experimental and clinical evidences to select " which D for which patient". |
| Q35189516 | Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study |
| Q91554403 | Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial |
| Q38228157 | Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review. |
| Q44445062 | Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia |
| Q38363615 | Emerging drugs for secondary hyperparathyroidism. |
| Q37123402 | Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism |
| Q84513486 | Emerging roles for osteoprotegerin and receptor activator of nuclear factor-kappaB in the vascular system |
| Q39718509 | Encephalopathy in a dialysis patient treated with lanthanum carbonate (LC). |
| Q91055406 | Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD) |
| Q34758018 | Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study |
| Q87154313 | Evaluation of renal function in elderly patients: performance of creatinine-based formulae versus the isotopic method using 99mTc-diethylene triamine pentaacetic acid |
| Q99241069 | Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait? |
| Q37988101 | Extracorporeal ultrafiltration in heart failure and cardio-renal syndromes. |
| Q41186366 | FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde |
| Q50932198 | Fetuin-A gene expression, synthesis and release in primary human hepatocytes cultured in a galactosylated membrane bioreactor. |
| Q81240805 | Gene polymorphisms and serum alpha-2-Heremans-Schmid levels in Italian haemodialysis patients |
| Q99241010 | Glucagon-like peptide-1 receptor and sarcoglycan delta genetic variants can affect cardiovascular risk in chronic kidney disease patients under hemodialysis |
| Q40668951 | HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. |
| Q40545006 | Hepatitis C virus outbreak in a haemodialysis unit: learning from failures. |
| Q90752349 | High-phosphate induced vascular calcification is reduced by iron citrate through inhibition of extracellular matrix osteo-chondrogenic shift in VSMCs |
| Q35611102 | Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach |
| Q64228366 | Hyperphosphatemia: a novel risk factor for mortality in chronic kidney disease |
| Q45983669 | Importance of vitamin D receptor activation in clinical practice. |
| Q83169476 | Inflammation and vascular calcification in chronic kidney disease: the role of Fetuin-A |
| Q43809739 | Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients |
| Q53671304 | Introduction: Mineral bone disorder is a key player in chronic kidney disease. |
| Q50227539 | Iron citrate reduces high phosphate-induced vascular calcification by inhibiting apoptosis |
| Q80112163 | Is PTH a risk factor for cardiovascular calcifications in haemodialysis? |
| Q34403555 | Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? |
| Q51835518 | Klotho-FGF23, cardiovascular disease, and vascular calcification: black or white? |
| Q40837665 | Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? |
| Q79410882 | Lanthanum carbonate--new data on parathyroid hormone control without liver damage |
| Q48298231 | Lanthanum carbonate: time to abandon prejudices? |
| Q44052669 | Lanthanum prevents high phosphate-induced vascular calcification by preserving vascular smooth muscle lineage markers. |
| Q53168271 | Low Dialysate Calcium: Between Low Arterial Calcification and Improved Low Bone Turnover. |
| Q47226485 | Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease |
| Q39051024 | Magnesium-based interventions for normal kidney function and chronic kidney disease. |
| Q35227651 | Magnesium: a renewed player of vascular ageing in diabetic CKD patients? |
| Q91871542 | Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly |
| Q37547201 | Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease. |
| Q81322783 | Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients |
| Q51818118 | Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients. |
| Q51732066 | Matrix-Gla protein and vascular calcification: the negative role of oral anticoagulant therapy. |
| Q104559436 | Medium Cut-Off Membranes: Incremental or Quantum Leap Innovation in Haemodialysis? |
| Q42727533 | Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation |
| Q37843788 | Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes |
| Q91192255 | Multicenter study on parathyroidectomy (PTX) in Italy: preliminary results |
| Q36482903 | Multimodal treatment of calcific uraemic arteriolopathy (calciphylaxis): a case series |
| Q92824059 | Native Hypovitaminosis D in CKD Patients: From Experimental Evidence to Clinical Practice |
| Q45983666 | New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. |
| Q86945644 | New endocrine biomarkers and cardiovascular disease: is it time for routinely screening? |
| Q38286695 | New insights into the FGF23-Klotho axis. |
| Q37881939 | New insights into the role of calcium-sensing receptor activation. |
| Q92104995 | New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology |
| Q38797862 | Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. |
| Q39003429 | Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury |
| Q93044584 | Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease |
| Q27011477 | Nutritional therapy, phosphate control and renal protection |
| Q91465215 | Nutritional vitamin D in CKD: Should we measure? Should we treat? |
| Q95616300 | Opponent's comments |
| Q57221176 | Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease |
| Q39658458 | Osteonectin (SPARC) Expression in Vascular Calcification: In Vitro and Ex Vivo Studies. |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q38111948 | Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice. |
| Q37497628 | Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". |
| Q36129859 | Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study |
| Q38436799 | Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. |
| Q81032434 | Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol |
| Q36192817 | Pathogenesis of vascular calcification in chronic kidney disease. |
| Q37417296 | Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease. |
| Q39276030 | Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate. |
| Q94913504 | Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America |
| Q90419900 | Percutaneous microwave ablation of renal angiomyolipomas in tuberous sclerosis complex to improve the quality of life: preliminary experience in an Italian center |
| Q34306062 | Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study |
| Q90761283 | Phosphate and bone fracture risk in chronic kidney disease patients |
| Q38253227 | Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool. |
| Q48282982 | Phosphate binders, past - present - future. A critical appraisal |
| Q38015103 | Phosphate control in peritoneal dialysis |
| Q38049170 | Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate |
| Q38768750 | Phosphate in Chronic Kidney Disease Progression. |
| Q37204047 | Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide |
| Q43104122 | Prevention and Treatment of CKD-MBD. |
| Q37152656 | Preventive measures and new pharmacological approaches of calcium and phosphate disorders. |
| Q41354300 | Pro: cardiovascular calcifications are clinically relevant |
| Q58715560 | Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care |
| Q79803683 | Progression of coronary artery calcification in predialysis patients |
| Q39447041 | Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion. |
| Q98200538 | Rationale for Medium Cutoff Membranes in COVID-19 Patients Requiring Renal Replacement Therapy |
| Q90516460 | Real-world data on healthcare resource consumption and costs before and after kidney transplantation |
| Q38087317 | Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. |
| Q94834787 | Renal outcomes in the ONTARGET study |
| Q42678949 | Reprint of: Vitamin D receptor activation and prevention of arterial ageing. |
| Q37882294 | Restoring the physiology of vitamin D receptor activation and the concept of selectivity. |
| Q45863496 | Role of vitamin D in the pathogenesis of chronic kidney disease |
| Q38015104 | Role of vitamin D receptor activators in peritoneal dialysis. |
| Q37988098 | Role of vitamin d receptor activators in cardio-renal syndromes |
| Q104575018 | SARS-CoV-2-related ARDS in a maintenance hemodialysis patient: case report on tailored approach by daily hemodialysis, noninvasive ventilation, tocilizumab, anxiolytics, and point-of-care ultrasound |
| Q38795448 | Secondary Hyperparathyroidism in End-Stage Renal Disease: No Longer a Matter for Surgeons? |
| Q84227703 | Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality |
| Q104488234 | Serum PTH levels in dialysis: better safe than sorry |
| Q80251431 | Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients |
| Q36443804 | Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. |
| Q44609785 | Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia |
| Q49142843 | Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement |
| Q90480569 | Small steps towards the potential of 'preventive' treatment of early phosphate loading in chronic kidney disease patients |
| Q40319543 | Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperparathyroidism in a haemodialysis patient. |
| Q38833461 | Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies |
| Q50090315 | The Cardiovascular Burden in End-Stage Renal Disease. |
| Q42879074 | The Control of Hyperphosphatemia in Renal Failure: Between Vascular Calcification and Inflammation |
| Q42735739 | The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control |
| Q35576108 | The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial |
| Q89821670 | The Home Jail Haemodialysis: a simple way to save money and improve security |
| Q91485812 | The Importance of Adherence in the Treatment of Secondary Hyperparathyroidism |
| Q93005076 | The Key Role of Phosphate on Vascular Calcification |
| Q91926539 | The Role of Vitamin K in Vascular Calcification |
| Q41845704 | The beneficial impact of vitamin D treatment in CKD patients: what's next? |
| Q54440135 | The calcimimetic calindol prevents high phosphate-induced vascular calcification by upregulating matrix GLA protein. |
| Q83161408 | The calciotropic hormones PTH and vitamin D: from bone to blood vessels |
| Q60220155 | The combination of lanthanum chloride and the calcimimetic calindol delays the progression of vascular smooth muscle cells calcification |
| Q90293744 | The effects of citrate dialysate in hemodialysis on polymorphonuclear elastase interaction with tissue factor and its inhibitor |
| Q44111648 | The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats |
| Q50233276 | The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease |
| Q37882298 | The impact of paricalcitol on left ventricular hypertrophy. |
| Q85836436 | The link between vitamin D, parathyroid hormone, and cardiovascular disease |
| Q36117940 | The mechanism of calcium deposition in soft tissues. |
| Q47713002 | The role of FGF-23 in CKD patients still needs to be clarified |
| Q38793054 | The role of phosphate in kidney disease |
| Q91572497 | The role of uric acid in mineral bone disorders in chronic kidney disease |
| Q82462140 | The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders? |
| Q39178220 | The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents |
| Q53314344 | The vitamin D system: a crosstalk between the heart and kidney. |
| Q91491569 | Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis |
| Q73789137 | Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder |
| Q26781820 | Treatment Failure of Active Vitamin D Therapy in Chronic Kidney Disease: Predictive Factors |
| Q51688448 | Treatment of cardiovascular calcification in uremia. |
| Q39374348 | Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide |
| Q49618375 | Treatments for secondary hyperparathyroidism in hemodialysis |
| Q49677711 | Troponin I Levels in Asymptomatic Hemodialysis Patients |
| Q58598022 | Tuberous sclerosis complex: new insights into clinical and therapeutic approach |
| Q91844376 | Update on ANCA-associated vasculitis: from biomarkers to therapy |
| Q91380569 | Uremic Patients with Increased Vascular Calcification Score Have Serum with High Calcific Potential: Role of Vascular Smooth Muscle Cell Osteoblastic Differentiation and Apoptosis |
| Q46291139 | VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey |
| Q44261849 | VDRAs versus calcimimetics: better safe than sorry? |
| Q37722176 | Vascular calcification and cardiovascular outcome in dialysis patients: the role of gene polymorphisms |
| Q37018450 | Vascular calcification and uremia: what do we know? |
| Q37881930 | Vascular calcification in chronic kidney disease: a changing scenario. |
| Q39028354 | Vascular calcification in chronic kidney disease: different bricks in the wall? |
| Q36368170 | Vascular calcification in uremic conditions: new insights into pathogenesis. |
| Q95550446 | Vitamin D Therapy: An Update |
| Q38845223 | Vitamin D in Kidney Transplant Recipients: Mechanisms and Therapy. |
| Q38803449 | Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology |
| Q39275892 | Vitamin D metabolism and potential effects of vitamin D receptor modulation in chronic kidney disease. |
| Q39519961 | Vitamin D: something new under the sun. |
| Q61818267 | Vitamin K in Chronic Kidney Disease |
| Q53087440 | Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. |
| Q37904909 | What would we like to know, and what do we not know about fibroblast growth factor 23? |
| Q41880565 | Where is the link between mineral bone markers and cardiovascular disease in CKD? |
| Q42728557 | Which outcome in chronic kidney disease-mineral and bone disorder patients? |
| Q42562972 | Which vitamin D in CKD-MBD? The time of burning questions |
| Q80368993 | Work ability and health status in dialysis patients |
| Q88072296 | [Utilization of alfacalcidol and active vitamin D analogs in chronic kidney disease] |
| Q43818206 | p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium |
Search more.